BAUSCH + LOMB CORP
BLCONYSETrading Snapshot
- Day Range
- $18.46 β $20.42
- 52-Week Range
- $14.44 β $20.43
- Volume (shares)
- 4,106,217
- Avg Volume (shares)
- β
- Shares Outstanding
- 357.2M
- Next Earnings
- 2026-10-28
Fundamentals Snapshot
- Annual Revenue
- $5.10B
- Last Q Revenue
- $1.39B
- P/E Ratio
- -65.9
- P/S Ratio
- 1.3x
- EPS (TTM)
- $-0.31
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.7%
BAUSCH + LOMB CORP
BLCOAbout BAUSCH + LOMB CORP
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcript

Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.18 per share a year ago.

Bausch + Lomb (NYSE:BLCO) Shares Down 5.8% β Whatβs Next?
Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report)'s stock price fell 5.8% during mid-day trading on Monday. The company traded as low as $16.13 and last traded at $16.2990. Approximately 154,963 shares traded hand

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results o